These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32043746)

  • 1. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease.
    Thomas PWA; Chin PKL; Barclay ML
    Intern Med J; 2021 Mar; 51(3):341-347. PubMed ID: 32043746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
    Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK
    Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
    Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
    Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.
    Ricciuto A; Dhaliwal J; Walters TD; Griffiths AM; Church PC
    J Crohns Colitis; 2018 Nov; 12(11):1302-1315. PubMed ID: 30107416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
    Mitrev N; Leong RW
    Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do patients with inflammatory bowel disease want their biological therapy administered?
    Allen PB; Lindsay H; Tham TC
    BMC Gastroenterol; 2010 Jan; 10():1. PubMed ID: 20064220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
    Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK
    Therap Adv Gastroenterol; 2024; 17():17562848241230902. PubMed ID: 38406794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.